GEAP202415866A - 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents - Google Patents

3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Info

Publication number
GEAP202415866A
GEAP202415866A GEAP202415866A GEAP2024015866A GEAP202415866A GE AP202415866 A GEAP202415866 A GE AP202415866A GE AP202415866 A GEAP202415866 A GE AP202415866A GE AP2024015866 A GEAP2024015866 A GE AP2024015866A GE AP202415866 A GEAP202415866 A GE AP202415866A
Authority
GE
Georgia
Prior art keywords
diamino
pro
derivatives
pharmaceutical compositions
compositions containing
Prior art date
Application number
GEAP202415866A
Other languages
English (en)
Inventor
Ana Leticia Maragno
Patrice Desos
Frédéric Collan
Maïa Chanrion
Jerome-Benoit Starck
Mátyás Pál Timári
Marianna Szigeti
Ágnes Strofek
Monika Rudasová
Miklos Nyerges
Márk Molnár
Zoltán Madarász
András Herner
Petra Dunkel
András Kotschy
Attila Paczal
Tibor Novák
Paul Webb
Rachel Jane Parsons
Mark Philip Dodsworth
Simon Bedford
James Brooke Murray
James Edward Paul Davidson
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of GEAP202415866A publication Critical patent/GEAP202415866A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GEAP202415866A 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents GEAP202415866A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19188747 2019-07-29

Publications (1)

Publication Number Publication Date
GEAP202415866A true GEAP202415866A (en) 2024-06-10

Family

ID=67514281

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP202415866A GEAP202415866A (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
GEAP202015866A GEP20247670B (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP202015866A GEP20247670B (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Country Status (24)

Country Link
US (1) US20220289734A1 (enExample)
EP (1) EP4003988A1 (enExample)
JP (1) JP7646626B2 (enExample)
KR (1) KR20220042182A (enExample)
CN (1) CN114450283B (enExample)
AR (1) AR119493A1 (enExample)
AU (1) AU2020322072A1 (enExample)
BR (1) BR112022001330A2 (enExample)
CA (1) CA3148502A1 (enExample)
CL (1) CL2021003594A1 (enExample)
CO (1) CO2022000700A2 (enExample)
CR (1) CR20220014A (enExample)
DO (1) DOP2022000015A (enExample)
GE (2) GEAP202415866A (enExample)
IL (1) IL289932B2 (enExample)
JO (1) JOP20220006A1 (enExample)
MX (1) MX2022001161A (enExample)
PE (1) PE20220704A1 (enExample)
PH (1) PH12022550018A1 (enExample)
PY (1) PY2039849A (enExample)
SA (1) SA522431498B1 (enExample)
TW (1) TWI900486B (enExample)
UY (1) UY38809A (enExample)
WO (1) WO2021018857A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021386367A1 (en) * 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
JP2024505562A (ja) * 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
AU2023271885A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
EA201001030A1 (ru) * 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG11201709837RA (en) * 2015-05-29 2017-12-28 Teijin Pharma Ltd PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Also Published As

Publication number Publication date
EP4003988A1 (en) 2022-06-01
KR20220042182A (ko) 2022-04-04
CR20220014A (es) 2022-03-02
SA522431498B1 (ar) 2025-04-13
TW202118761A (zh) 2021-05-16
CL2021003594A1 (es) 2022-11-18
US20220289734A1 (en) 2022-09-15
DOP2022000015A (es) 2022-05-15
WO2021018857A1 (en) 2021-02-04
BR112022001330A2 (pt) 2022-05-17
JP2022542937A (ja) 2022-10-07
UY38809A (es) 2021-02-26
AU2020322072A1 (en) 2022-02-10
IL289932A (en) 2022-03-01
CA3148502A1 (en) 2021-02-04
CO2022000700A2 (es) 2022-02-07
MX2022001161A (es) 2022-02-22
IL289932B1 (en) 2025-10-01
CN114450283A (zh) 2022-05-06
GEP20247670B (en) 2024-09-25
JOP20220006A1 (ar) 2023-01-30
NZ784583A (en) 2025-02-28
IL289932B2 (en) 2026-02-01
PE20220704A1 (es) 2022-05-04
PY2039849A (es) 2021-05-06
PH12022550018A1 (en) 2022-10-17
CN114450283B (zh) 2024-05-07
TWI900486B (zh) 2025-10-11
AR119493A1 (es) 2021-12-22
JP7646626B2 (ja) 2025-03-17

Similar Documents

Publication Publication Date Title
GEP20247670B (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
SA521430853B1 (ar) Nlrp3 مثبطات جسيم التهابي
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
GEAP202315746A (en) Protein tyrosine phosphatase inhibitors
MY209609A (en) Immunomodulators, compositions and methods thereof
PH12020550786A1 (en) Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
GEP20257823B (en) Amino quinazoline derivatives as p2x3 inhibitors
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
ZA202004023B (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
EA200700138A1 (ru) Замещённые индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
MY209034A (en) Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
EA202090448A1 (ru) Дигидрооксадиазиноны
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
PH12021551873A1 (en) Hydroxypyridoxazepines as nrf2 activators
MX2023005039A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3.
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MX2020008982A (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.
PH12021550258A1 (en) Cdk8/19 inhibitors
PH12021552133A1 (en) Aromatic derivatives, preparation methods, and medical uses thereof
PH12021550093A1 (en) Compounds for use in the treatment of fascioliasis